"By bringing Alzheimer's blood-based biomarker testing into primary care, we can help patients and their clinicians get answers sooner." ...

Two FDA-approved Alzheimer's drugs, lecanemab and donanemab, are now being tested as an alzheimers prevention drug in people ...

The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomography (PET) scans, a non-invasive brain scan crucial for ...

A study by investigators at Mass General Brigham has found that a blood test of plasma phosphorylated tau 217 (pTau217), an Alzheimer's disease biomarker, can predict the progression of amyloid PET ...

The Centers for Medicare & Medicaid Services (CMS) has expanded coverage of brain amyloid positron-emission tomography (PET) imaging for the diagnosis of Alzheimer's disease (AD). The CMS decision, ...

WASHINGTON DC - JUNE 20, 2023 Jay Reinstein, who suffers from Alzheimer's, prepares to receive a PET scan at MedStar Georgetown University Hospital in Washington, DC. (Photo by Michael Robinson Chávez ...

Amyloid PET scans provide in-vivo evidence of Alzheimer's disease (AD) pathology. However, due to their high cost and limited insurance coverage, they are not widely used in clinical settings outside ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed more than 10,000 PET scans of patients from the IDEAS study. Measurement of Centiloids from ...

The recent FDA approval of Leqembi, the latest anti-amyloid drug, is undoubtedly a breakthrough for the field, providing a new way to slow the advancement of mild cognitive impairment or early-stage ...